Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity

Executive Summary

The first biosimilar with interchangeability status compared to its reference will be entitled to one year of exclusivity, a largely overlooked advantage in the early days of the US biosimilar market.

You may also be interested in...



Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?

Former FDA official says the pathway is needed to avoid wasted sponsor time and effort.

Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?

Former FDA official says the pathway is needed to avoid wasted sponsor time and effort.

Tentative Biosimilar Approvals Under Consideration By FDA

Concept could help sponsors who reach approvability but must wait several years before reference product exclusivity expires.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel